Head-to-head · WeighScore
DoctorAdam vs Kin Meds
By GLP-1 ScorecardUpdated
Score comparison
DoctorAdam has the higher recorded score — 75.9/100 to 69.1/100.
DoctorAdam grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. DoctorAdam is a Shopify-based telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral tablet forms, with flat all-in monthly pricing covering physician evaluation, medication, and free shipping.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | DoctorAdam | Kin Meds |
|---|---|---|
| WeighScore | 75.9/100 | 69.1/100 |
| Grade | C | C |
| Site position | #55 | #148 |
| Semaglutide | $129/mo (starting dose, compounded) | $149/mo (brand Wegovy) |
| Tirzepatide | $229/mo (starting dose, compounded) | $149/mo (brand Zepbound) |
| Coverage | 44 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #55 · C
Strengths
- Offers both injection and oral tablet forms of compounded semaglutide and tirzepatide
- Flat all-in pricing — physician evaluation, medication, and free shipping included
- Named pharmacy partners: Olympia Pharmaceuticals (Orlando, FL) and Carie Boyd Pharmaceuticals (Irving, TX)
- LegitScript certified with 4.8/5 Trustpilot score from 5,400+ reviews and 100K+ patients
- No hidden fees, no required recurring commitment, full refund if not prescribed
What to consider
- Compounded medications are not FDA-approved individual drugs
- No labs or dedicated coaching disclosed on public pages
- Only 44 states served — AK, MA, MS, NJ, RI, and VT excluded despite homepage '50 states' claim
- Dose-tier pricing not published; only starting prices visible without quiz
- Shopify-based store rather than a dedicated health platform
Site position #148 · C
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Strengths
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
What to consider
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.